Table 1.

Characteristics of the studies included in the review

Author	Year	Country	Study type	Number of TJA	Group	Age (years)	Gender F/M	BMI	Diagnosis	Type of TJA	Follow-Up	NOS
Stambough et al.	2017	USA	Retrospective	4186	Screening	THA 58.2 ± 13.5 TKA 63.1 ± 9.6	1146/903	THA 29.0 ± 5.0 TKA 32.1 ± 5.8	NM	1003TKA/1202THA	90 days	8
					Control	THA 57.2 ± 14.1 TKA 63.3 ± 10.0	1031/833	THA 29.3 ± 5.9 TKA 32.9 ± 6.4	NM	836TKA/1145THA
Hofmann et al.	2017	USA	Retrospective	1034	Screening	61.5 ± 11.6	324/214	NM	degenerative joint disease	306TKA/232 THA	≥ 1 year	8
					Control	60.6 ± 12.3	279/217	NM		294TKA/202THA
Hadley et al.	2010	USA	Retrospective	2058	Screening	NM	NM	NM	NM	TKA THA	1 year	7
					Control	NM	NM	NM	NM
Sankar et al.	2005	UK	Prospective	395	Screening	68.53 (48–77)	141/90	NM	OA: 381, RA: 12, AS: 2	106TKA/125THA	NM	7
					Control	67.39 (51–79)	106/58	NM		79TKA/85THA
Jeans et al.	2018	UK	retrospective	12911	Screening	68.6 (16–99)	5125/4193	29.9 (15.6–61)	NM	TKA THA	NM	6
					Control	68.5 (22–100)	1940/1653	29.5 (17.3–50.2)	NM
Rao et al.	2011	USA	Prospective	2026	Screening	NM	NM	NM	NM	TKA THA	2 years	6
					Control	NM	NM	NM	NM
Hacek et al.	2008	USA	Retrospective	1495	Screening	69.0	565/347	NM	NM	(709TKA/786THA)	1 year	8
					Control	69.1	356/227	NM	NM
Pelfort et al.	2019	Spain	Retrospective	803	Screening	72.4 ± 6.9	278/125	NM	NM	TKA	1 year	8
					Control	72.2 ± 6.8	266/134	NM	NM
Sporer et al.	2016	UKA	Retrospective	11133	Screening	NM	5819/3972	NM	NM	6175TKA/3661THA	30 days	7
					Control	NM	847/593	NM	NM	924TKA/ 516THA

TJA total joint arthroplasty, F female, M male, BMI body mass index, THA total hip arthroplasty, TKA total knee arthroplasty, NM not mentioned, NOS Newcastle-Ottawa Scale, OA osteoarthritis, RA rheumatoid arthritis, AS ankylosing spondylitis